Add BrightSurf on Google Email

Hunter Medical Research Institute


Researchers discover potential new melanoma treatment giving hope to patients

A phase II study found that treating late-stage, treatment-resistant melanoma patients with a combination of Azacitidine and Carboplatin significantly increases their survival times. The treatment re-sensitized cancer cells to immunotherapy, allowing the body's immune system to fight the cancer.

SourceHunter Medical Research Institute·JournalCancer Research Communications·TypeRandomized controlled/clinical trial·DateSep 5, 2022